A5019535702- Multiple Sclerosis Research Studies
- Brain Tumor Detection and Classification
- Ultrasound Imaging and Elastography
- Systemic Lupus Erythematosus Research
- Ultrasound and Hyperthermia Applications
- Radiomics and Machine Learning in Medical Imaging
- Neurological Disease Mechanisms and Treatments
- Advanced Neuroimaging Techniques and Applications
- Advanced MRI Techniques and Applications
- Medical Imaging and Analysis
- Peripheral Neuropathies and Disorders
- Rheumatoid Arthritis Research and Therapies
- Medical Image Segmentation Techniques
- Effects of Vibration on Health
- RNA regulation and disease
- Sphingolipid Metabolism and Signaling
- Viral Infections and Immunology Research
- Circular RNAs in diseases
- MicroRNA in disease regulation
- Medical Research and Treatments
- RNA Research and Splicing
- Flavonoids in Medical Research
- Monoclonal and Polyclonal Antibodies Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- MRI in cancer diagnosis
Brigham and Women's Hospital
2015-2022
Harvard University
2015-2022
MR imaging can be used to measure structural changes in the brains of individuals with multiple sclerosis and is essential for diagnosis, longitudinal monitoring, therapy evaluation. The North American Imaging Multiple Sclerosis Cooperative steering committee developed a uniform high-resolution 3T protocol relevant quantification cerebral lesions atrophy implemented it at 7 sites across United States. To assess intersite variability scan data, we imaged volunteer relapsing-remitting MS...
<h3>Importance</h3> MicroRNAs (miRNAs) are promising multiple sclerosis (MS) biomarkers. Establishing the association between miRNAs and magnetic resonance imaging (MRI) measures of disease severity will help define their significance potential impact. <h3>Objective</h3> To correlate circulating in serum patients with MS to brain spinal MRI. <h3>Design, Setting, Participants</h3> A cross-sectional study comparing miRNA samples MRI metrics was conducted at a tertiary referral center. Two...
Technological advances in passive digital phenotyping present the opportunity to quantify neurological diseases using new approaches that may complement clinical assessments. Here, we studied multiple sclerosis (MS) as a model disease for investigating physiometric and environmental signals. The objective of this study was assess feasibility correlation wearable biosensors with traditional measures disability both clinic free-living MS patients. This is single site observational cohort...
ABSTRACT BACKGROUND AND PURPOSE A pipeline for fully automated segmentation of 3T brain MRI scans in multiple sclerosis (MS) is presented. This morphometry (3TM) provides indicators MS disease progression from multichannel datasets with high‐resolution 3‐dimensional T1‐weighted, T2‐weighted, and fluid‐attenuated inversion‐recovery (FLAIR) contrast. 3TM segments white (WM) gray matter (GM) cerebrospinal fluid (CSF) to assess atrophy WM lesion (WML) volume. METHODS To address nonuniform...
To determine whether peripheral immune responses as measured by serum antigen arrays are linked to cerebral MRI measures of disease severity in multiple sclerosis (MS).In this cross-sectional study, samples were obtained from patients with relapsing-remitting MS (n = 21) and assayed using that contained 420 antigens including CNS-related autoantigens, lipids, heat shock proteins. Normalized compartment-specific global brain volumes 3-tesla surrogates atrophy, gray matter fraction (GMF),...
To explore (i) the variability of upper cervical cord area (UCCA) measurements from volumetric brain 3D T1 -weighted scans related to gradient nonlinearity (GNL) and subject positioning; (ii) effect vendor-implemented GNL corrections; (iii) easily applicable methods that can be used retrospectively correct data.A multiple sclerosis patient was scanned at seven sites using 3T MRI scanners with same protocol without GNL-distortion correction. Two healthy subjects a phantom were additionally...
BackgroundCerebral gray matter (GM) atrophy has clinical relevance in multiple sclerosis (MS). Fingolimod known efficacy on and conventional MRI findings MS; the effect GM is unknown.ObjectiveTo explore fingolimod's treatment cerebral over two years patients with relapsing forms of MS.Design/methodsPatients starting fingolimod [n = 24, age (mean ± SD) 41.2 11.6 years, Expanded Disability Status Scale (EDSS) score 1.1 1.4; 58% women] were compared to untreated 29, 45.7 8.4 EDSS 1.0 1.2; 93%...
Objective: Test a new version of the Magnetic Resonance Disease Severity Scale (v.3 = MRDSS3) for multiple sclerosis (MS), incorporating cortical gray matter lesions (CLs) from 3T MRI. Background: MRDSS1 was cerebral MRI-defined composite scale MS disease severity combining T2 lesion volume (T2LV), ratio T1 to T2LV (T1/T2), and whole brain atrophy (brain parenchymal fraction-BPF). MRDSS2 expanded include fraction (GMF) upper cervical spinal cord area (UCCA). We tested contribution CLs...
Assess the sensitivity of Magnetic Resonance Disease Severity Scale (MRDSS), based on cerebral lesions and atrophy, for treatment monitoring glatiramer acetate (GA) in relapsing-remitting multiple sclerosis (MS). This retrospective non-randomized pilot study included patients who started daily GA [n = 23, age (median, range) 41 (26.2, 53.1) years, Expanded Disability Status (EDSS) score 1.0 (0, 3.5)], or received no disease-modifying therapy (noDMT) 21, 44.8 (28.2, 55.4), EDSS 0 2.5)] 2...
Monitoring patients with multiple sclerosis (MS) for “no evidence of disease activity” (NEDA) may help guide disease-modifying therapy (DMT) management decisions. Whereas surveillance brain magnetic resonance imaging (MRI) is common, the role spinal cord monitoring NEDA unknown.To evaluate and 3T MRI in 1-year evaluation NEDA.Of 61 study (3 clinically isolated syndrome, 56 relapsing-remitting, 2 secondary progressive), (91.8%) were receiving DMT. The included fluid-attenuated inversion...
Abstract Background and Purpose Whole‐brain atrophy is a standard outcome measure in multiple sclerosis ( MS ) clinical trials as assessed by various software tools. The effect of processing method on the validity such data obtained from high‐resolution 3T MRI not known. We compared two commonly used methods quantifying whole‐brain atrophy. Methods Three‐dimensional T1‐weighted FLAIR images were at n = 61) normal control NC , 30) groups. was automated pipelines: (a) SPM 8 to derive brain...
Objective: To evaluate differences in cortical thickness from 1.5T vs. 3T MRI multiple sclerosis (MS) patients normal controls (NC). Background: Cortical thinning on is an early feature MS and related to neurologic impairment. The measurement of challenging due the complex anatomy involved. growing availability higher field strength brings potential provide more reliable segmentation. Methods: We studied 15 [11 relapsing 4 progressive types, 12 (80[percnt]) women, age (mean±SD) 50.3±8 years,...
OBJECTIVE: Compare T1 spin echo (T1SE) and gradient (T1GE) sequences in detecting hypointense brain lesions patients with multiple sclerosis (MS). BACKGROUND: Chronic on T1SE MRI scans are an accepted surrogate of severe demyelination axonal loss MS. The role T1GE images the detection such has not been clarified. DESIGN/METHODS: In 45 MS [age (mean +SD) 42.3+8.3 years; Expanded Disability Status Scale (EDSS) score 3.5+2.0; 37 relapsing-remitting (RR); 8 secondary progressive (SP)], cerebral...
OBJECTIVE: Assess the accuracy of novel automated multi-channel high-resolution MRI morphometry in multiple sclerosis (MS) for long-term routine assessment from clinically suitable 3T images. BACKGROUND: We have developed new software segmentation and measurement whole brain lesion burden atrophy images MS. The system is geared toward assessment, i.e. optimized consistency follow-up across a wide spectrum disease burden. METHODS: protocol (3T Siemens Skyra, 20-channel headcoil) comprised...
Objective: To test a new version of the Magnetic Resonance Disease Severity Scale (v.3 = MRDSS3) for multiple sclerosis (MS), incorporating cortical gray matter lesions (CLs) from 3T MRI. Background: MRDSS1 was cerebral MRI-defined composite scale disease severity in MS combining T2 lesion volume (T2LV), ratio T1 hypointense to T2LV (T1/T2), and whole brain atrophy (brain parenchymal fraction-BPF). MRDSS2 expanded include global fraction (GMF) upper cervical spinal cord area (UCCA). We...
Objective: Assess the sensitivity of Magnetic Resonance Disease Severity Scale (MRDSS), based on cerebral lesions and atrophy, for treatment monitoring glatiramer acetate (GA) in relapsing-remitting multiple sclerosis (MS). Background: MRDSS is a MRI composite scale evaluating MS disease severity shown by atrophy with inclusion unique metric destructive potential lesions, intrasubject T1/T2 lesion ratio. Methods: This retrospective non-randomized study included patients who started daily GA...
OBJECTIVE: test the effect of a dual-sensitivity automated segmentation multiple sclerosis (MS) lesions in routinely acquired high-field MRI, specifically improvement specificity infratentorial lesion detection BACKGROUND: A new MS white matter (WML) from 3T MRI was developed, with adjustable tissue intensity modeling for different anatomical regions. We tested method’s on WML segmentation, region prone to false positives (FPs). DESIGN/METHODS: (Siemens Skyra; 20-channel headcoil) included...
To assess cerebral gray matter (GM) atrophy in patients with relapsing-remitting multiple sclerosis (RRMS) starting glatiramer acetate (GA) vs. benign RRMS (BMS).
To compare cerebral gray matter (GM) atrophy over two years in patients with relapsing forms of multiple sclerosis (MS) starting fingolimod vs. those untreated.